finasteride has been researched along with Genetic Predisposition in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Beck, R; da Silva, C; Katzer, T; Leite Junior, A | 1 |
| Ahmed, M; Cieza-Borrella, C; Eeles, R; Goh, C; Kote-Jarai, Z; Saunders, E; Schumacher, FR | 1 |
| Ambrosone, CB; Figg, WD; Goodman, PJ; Hsing, A; Lippman, SM; Neuhouser, ML; Platek, ME; Platz, EA; Reichardt, JKV; Santella, RM; Stanczyk, FZ; Tang, L; Tangen, CM; Thompson, IM; Till, C; Wu, Y; Yao, S | 1 |
| Bhargava, S | 1 |
| Cauci, S; Cecchin, E; De Mattia, E; Mazzon, G; Toffoli, G; Trombetta, C | 1 |
| Beadles-Bohling, AS; Crabbe, JC; Finn, DA; Ford, MM; Gililland-Kaufman, KR; Mark, GP; Snelling, C; Tanchuck, MA | 1 |
| Alsantali, A; Shapiro, J | 1 |
| Rathnayake, D; Sinclair, R | 1 |
| Camarena-Reynoso, HR; Jimenez-Rios, MA; Ketchum, NS; Liang, Y; Louden, C; Thompson, IM | 1 |
| Banka, N; Bunagan, MJ; Shapiro, J | 1 |
| Hanneken, S; Kruse, R; Nöthen, MM; Ritzmann, S | 1 |
| Ford, LG; Parnes, HL; Thompson, IM | 1 |
| Margiotti, K; Novelli, G; Reichardt, JK; Sangiuolo, F | 1 |
| Stephenson, J | 1 |
| Brooks, JD; DePrimo, SE; Shinghal, R; Vidanes, G | 1 |
8 review(s) available for finasteride and Genetic Predisposition
| Article | Year |
|---|---|
Physiopathology and current treatments of androgenetic alopecia: Going beyond androgens and anti-androgens.
Topics: Adult; Alopecia; Androgen Antagonists; Finasteride; Genetic Predisposition to Disease; Hair; Humans; Low-Level Light Therapy; Male; Middle Aged; Minoxidil; Platelet-Rich Plasma; Prognosis; Risk Assessment; Treatment Outcome | 2019 |
Androgens and hair loss.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Administration, Cutaneous; Alopecia; Androgens; Animals; Azasteroids; Dutasteride; Enzyme Inhibitors; Finasteride; Genetic Predisposition to Disease; Hair; Humans; Male; Minoxidil; Risk Factors; Testosterone; Treatment Outcome | 2009 |
Male androgenetic alopecia.
Topics: Administration, Oral; Administration, Topical; Alopecia; Androgen Receptor Antagonists; Azasteroids; Combined Modality Therapy; Dutasteride; Finasteride; Genetic Predisposition to Disease; Hair; Humans; Male; Men's Health; Minoxidil; Polymorphism, Genetic; Receptors, Androgen | 2010 |
Pattern hair loss in men: diagnosis and medical treatment.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgens; Azasteroids; Dutasteride; Female; Finasteride; Genetic Predisposition to Disease; Hair Follicle; Humans; Male; Minoxidil; Vasodilator Agents | 2013 |
[Androgenetic alopecia. Current aspects of a common phenotype].
Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Alopecia; Disease Progression; Enzyme Inhibitors; Female; Finasteride; Genetic Predisposition to Disease; Hair; Hair Follicle; Humans; Male; Middle Aged; Minoxidil; Vasodilator Agents | 2003 |
Prevention of hormone-related cancers: prostate cancer.
Topics: Androgens; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Genetic Predisposition to Disease; Humans; Male; Models, Genetic; Polymorphism, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors | 2005 |
Pharmacogenetics of human androgens and prostatic diseases.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Finasteride; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Prostatic Hyperplasia; Prostatic Neoplasms; Receptors, Androgen | 2001 |
Prevention of prostate cancer.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adenocarcinoma; Androgen Antagonists; Androgens; Animals; Anticarcinogenic Agents; Antioxidants; Carotenoids; Case-Control Studies; Cohort Studies; Dietary Fats; Double-Blind Method; Enzyme Inhibitors; Finasteride; Genetic Predisposition to Disease; Humans; Incidence; Insulin-Like Growth Factor I; Life Style; Lycopene; Male; Mice; Mice, Transgenic; Micronutrients; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Hyperplasia; Prostatic Neoplasms; Racial Groups; Randomized Controlled Trials as Topic; Risk Factors; Selenium; Soybean Proteins; Vitamin D; Vitamin E | 2001 |
2 trial(s) available for finasteride and Genetic Predisposition
| Article | Year |
|---|---|
Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT.
Topics: 5-alpha Reductase Inhibitors; Aged; Biomarkers, Tumor; Case-Control Studies; Clinical Trials as Topic; DNA Mutational Analysis; Finasteride; Follow-Up Studies; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Male; Polymorphism, Single Nucleotide; Prognosis; Prostatic Neoplasms; Risk Factors; Survival Rate | 2020 |
Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Topics: 5-alpha Reductase Inhibitors; Aged; Aromatase; Case-Control Studies; Estrogens; Finasteride; Genetic Predisposition to Disease; Genotype; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Prostatic Neoplasms | 2018 |
5 other study(ies) available for finasteride and Genetic Predisposition
| Article | Year |
|---|---|
Increased DHT levels in androgenic alopecia have been selected for to protect men from prostate cancer.
Topics: Adult; Alopecia; Androgens; Cell Proliferation; Dihydrotestosterone; Finasteride; Gene Expression Regulation; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Models, Theoretical; Prostaglandin D2; Prostatic Neoplasms | 2014 |
A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation.
Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Drug-Related Side Effects and Adverse Reactions; Finasteride; Genetic Predisposition to Disease; Humans; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Prostatic Hyperplasia; Receptors, Androgen; Retrospective Studies; Surveys and Questionnaires | 2014 |
The neurosteroid environment in the hippocampus exerts bi-directional effects on seizure susceptibility in mice.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Alcohol-Induced Disorders, Nervous System; Animals; Anticonvulsants; Convulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epilepsy; Finasteride; Genetic Predisposition to Disease; Hippocampus; Mice; Mice, Transgenic; Neurons; Pentylenetetrazole; Pregnanolone; Substance Withdrawal Syndrome | 2008 |
The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study.
Topics: 5-alpha Reductase Inhibitors; Age Factors; Aged; Antineoplastic Agents, Hormonal; Biopsy; Chi-Square Distribution; Digital Rectal Examination; Finasteride; Genetic Predisposition to Disease; Humans; Incidence; Logistic Models; Male; Mass Screening; Mexico; Middle Aged; Multivariate Analysis; Neoplasm Grading; Odds Ratio; Pedigree; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Referral and Consultation; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors | 2012 |
As genes differ, so should interventions for cancer.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Antineoplastic Agents; Enzyme Inhibitors; Finasteride; Genetic Predisposition to Disease; Humans; Male; Prostatic Neoplasms | 2001 |